U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362290) titled 'TSPO Occupancy in the Human Lung' on Sept. 30, 2025.
Brief Summary: The investigators would like to explore the role of TSPO in PAH using a pharmacological challenge agent (XBD173) to modulate TSPO function. In order to appropriately design experimental medicine studies examining TSPO function, the investigators first need an understanding of the relationship between XBD173 dose and occupancy of lung TSPO.
The aim of the proposed study, therefore, is to answer three questions:
1. What plasma concentrations of XBD173 are required to cause high occupancy of lung TSPO?
2. What doses of XBD173 are required to achieve these plasma con...